SRC and prostate carcinoma: Recently, with the deepening of the research on the mechanism of AR to regulate the progression of CaP, instead of inhibiting AR, new therapeutic research focuses on AR‐interacting proteins, such as Geldanamycin, an inhibitor of AR chaperone HSP90, to accelerate the degradation of AR, and SRC inhibitor of AR co‐regulator agent Sangivamycin blocks the transcriptional activity of AR, etc These new approaches have brought dawn to the treatment of prostate cancer.23